期刊文献+

急性心肌梗死围PCI手术期替罗非班的应用及安全性分析

The application and safety analysis of tirofiban on pci perioperative period acute myocardial infarction
下载PDF
导出
摘要 目的探讨替罗非班应用于急性心肌梗死(AMI)围PCI手术期的疗效及安全性。方法将38例AMI患者随机分为观察组及对照组各19例,对照组围PCI手术期采取常规治疗,观察组围PCI手术期采取常规治疗加替罗非班治疗。观察两组患者血小板聚集率、术中出血情况及术后不良心血管事件(MACE)发生率。结果观察组血小板聚集率显著低于对照组(P<0.01),MACE发生率低于对照组(P<0.05),术后出血情况与对照组无统计学差异(P>0.05)。结论替罗非班用于AMI患者围PCI手术期抗血小板聚集效果好,安全性高,值得进一步研究。 Objective To investigate the effect of tirofiban for acute myocardial infarction (AMI) in PCI operation period. Methods 38 cases of AMI were randomly divided into observation group and control group with 19 cases in each group. The control group during the PCI operation period was adopted to conventional treatment, and the observation group in PCI operation period take routine treatment with tirofiban therapy. Two groups were observed in patients with platelet aggregation rate, intraoperative bleeding and postoperative adverse cardiovascular events (MACE) incidence. Re- suits In the observation group, the platelet aggregation rate was significantly lower than that of control group (P〈0.01), MACE were lower than those of control group (P〈0.05). The postoperative bleeding and the control group showed no significant difference (P〉0.05). Conclusion Tirofiban in AMI patients during operation period of PCI has antiplatelet aggregation effect and high safety.
出处 《西部医学》 2012年第11期2134-2135,共2页 Medical Journal of West China
基金 河北省卫生厅课题(编号:201101241)
关键词 急性心肌梗死 PCI 替罗非班 安全性 Acute myocardial infarction PCI Tirofiban Safety
  • 相关文献

参考文献5

二级参考文献19

  • 1曹绪芬,卢清龙,韩立宪,袁琛,王钢,赵荣诚,王娟,程晓明.盐酸替罗非班在急性心肌梗死患者急诊冠状动脉介入治疗围术期的应用[J].中国介入心脏病学杂志,2006,14(3):176-178. 被引量:10
  • 2徐立,杨新春,王乐丰,葛永贵,王红石,李惟铭,倪祝华,刘宇,崔亮.提前应用替罗非班对急性ST段抬高心肌梗死患者急诊介入治疗疗效的影响[J].中华心血管病杂志,2006,34(11):983-986. 被引量:48
  • 3严金川,马根山,冯毅,沈成兴,戴启明,朱建.国产替罗非班治疗急性冠状动脉综合征的安全性和有效性[J].中国介入心脏病学杂志,2007,15(2):96-98. 被引量:32
  • 4Eimouchi DA,Bates ER.Platelet glycoproteinⅡb/Ⅲa in-hibitor therapy in non2 ST segment elevation acute coro-nary syndromes.Minerva Cardioangiol,2003,51(5):547. 被引量:1
  • 5Rezkalla SH, Kloner RA. No-reflow phenomenon[J], Circulation, 2002,105 : 656-662. 被引量:1
  • 6Lee DP, Herity NA, Hiatt BL, et al . Adjunctive platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial[J]. Circulation, 2003,107 : 1497-1501. 被引量:1
  • 7Silber S, Albertsson P, Aviles F F, et al. Guidelines for percutaneous coronary interventions.The task force for percutaneous coronary interventions of the European society of cardiology [J]. Eur Heart J, 2005,26(8):804-847. 被引量:1
  • 8Piana R N, Paik G Y, Moscucci M, et al. Incidence and treatment of no reflow' after percutaneous coronary intervention [J]. Circulation, 1994,89,(6):2514-2518. 被引量:1
  • 9Kabbani S S, Watkins M W, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention [J]. Circulation, 2001,104(2): 181-186. 被引量:1
  • 10Adgey A A. An overview of the resuhs of clinical trials with glycoprotein Ⅱ b/Ⅲ a inhibitors [J]. Eur Heart J,1998,19 (Suppl D) :D10-D21. 被引量:1

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部